NeuroSense Therapeutics (NRSN) said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.
NeuroSense said it would keep full rights to PrimeC in other key territories.
The term sheet includes a "substantial" upfront payment" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.
A definitive agreement is expected to be finalized in Q1 2025, the company added.
NeuroSense's shares were down more than 16% in early trading Monday.
Price: 1.13, Change: -0.23, Percent Change: -16.91
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。